PharmaSGP Holding SE Logo

PharmaSGP Holding SE

Develops and markets leading natural OTC drugs for chronic conditions in the European market.

PSG | F

Overview

Corporate Details

ISIN(s):
DE000A2P4LJ5
LEI:
3912005CZ12PVVCIPT91
Country:
Germany
Address:
Lochhamer Schlag 1, 82166 Gräfelfing
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PharmaSGP Holding SE is a pharmaceutical company specializing in the development and marketing of a broad portfolio of leading over-the-counter (OTC) drugs and other healthcare products. The company focuses on pharmacy-exclusive remedies based on natural pharmaceutical active ingredients with documented efficacy and minimal known side effects. Its core brands are market leaders in Germany and other European countries for chronic indications, including rheumatic and nerve pain (RubaXX®, Restaxil®), sleep disorders (Baldriparan®), and sexual weakness (DESEO®, NERADIN®). Since launching its first product in 2012, PharmaSGP has expanded its business model across Europe. The company's growth is driven by organic brand development and strategic acquisitions, such as its 2021 purchase of an OTC brand portfolio from GSK.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-22 15:15
Pre-Annual General Meeting Information
PharmaSGP convenes extraordinary general meeting to resolve on Squeeze-out
English 7.3 KB
2025-09-19 14:15
Report Publication Announcement
English 3.9 KB
2025-09-11 09:00
Earnings Release
PharmaSGP publishes preliminary half-year figures for 2025
English 15.7 KB
2025-08-14 12:00
Delisting Announcement
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 1,315 additional shares…
English 6.8 KB
2025-08-11 13:00
Delisting Announcement
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 39,678 additional share…
English 6.8 KB
2025-08-08 11:47
Director's Dealing
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 873 additional shares o…
English 6.8 KB
2025-08-07 13:11
Director's Dealing
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 1,505 additional shares…
English 6.8 KB
2025-08-06 16:16
Delisting Announcement
PharmaSGP Holding SE: Delisting of PharmaSGP shares from Frankfurt Stock Exchan…
English 7.8 KB
2025-08-05 10:48
Director's Dealing
PharmaSGP Holding SE: Michael Rudolf, Tender of 4,169 shares within the public …
English 5.9 KB
2025-08-04 13:58
Delisting Announcement
PharmaSGP Holding SE: Dr. Clemens Fischer, Tender of a total of 6,062 addition…
English 6.6 KB
2025-07-28 17:04
Delisting Announcement
PharmaSGP Holding SE publishes joint reasoned statement of the Management Board…
English 9.2 KB
2025-07-28 14:11
Delisting Announcement
PharmaSGP Holding SE: FUTRUE GmbH, Tender of an additional total of 4,491 share…
English 6.9 KB
2025-07-24 15:30
Director's Dealing
PharmaSGP Holding SE: FUTRUE GmbH, buy
English 6.0 KB
2025-07-24 14:11
Delisting Announcement
FUTRUE GmbH submits request to implement squeeze-out of minority shareholders o…
English 8.2 KB
2025-07-23 17:38
Declaration of Voting Results & Voting Rights Announcements
English 13.0 KB

Automate Your Workflow. Get a real-time feed of all PharmaSGP Holding SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PharmaSGP Holding SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-25 FUTRUE GmbH Close relation Buy None 12,145,250.00 EUR
2022-10-05 MMI Leisure & Capital Management GmbH Close relation Buy None 125,383.20 EUR
2022-10-05 Hillen, Ingo Board Buy None 1,048.00 EUR
2022-10-05 MMI Leisure & Capital Management GmbH Close relation Buy None 26.60 EUR
2022-05-30 Wittig, Dr. Thomas Supervisory board Buy None 138,953.80 EUR
2022-05-30 Schröter, Jasmin Close relation Buy None 119,660.00 EUR
2022-05-30 Simon-Schröter, Dr. Wolfram Other Buy None 10,040.00 EUR
2022-04-25 FUTRUE GmbH Close relation Buy None 208,180.53 EUR
2022-04-25 MMI Leisure & Capital Management GmbH Close relation Sell None 197,193.60 EUR
2022-04-25 Bloching, Prof. Dr. Micha Supervisory board Sell None 171,825.00 EUR

Peer Companies

Company Country Ticker View
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland COS
COSMO Pharmaceuticals N.V. Logo
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
Netherlands COPN
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea 060590
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan 4894
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea 365270
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany CVAC
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea 372320
Cyfuse Biomedical K.K. Logo Japan 4892

Talk to a Data Expert

Have a question? We'll get back to you promptly.